# Basking Biosciences, Inc.

> Basking Biosciences is a clinical-stage biopharmaceutical company developing the first reversible thrombolytic therapy for acute ischemic stroke. Its lead candidate, BB-031, is a first-in-class RNA aptamer that inhibits von Willebrand Factor to break up clots quickly, paired with a companion reversal agent, BB-025, that can switch the drug's activity off in minutes if bleeding occurs. Spun out of research begun at Duke University and founded in 2019, the company is based in the Research Triangle of North Carolina and is advancing BB-031 through a Phase 2 RAISE trial.

- **Founded:** 2019
- **Headquarters:** Morrisville, North Carolina, United States
- **Founders:** Bruce A. Sullenger, Ph.D. (Co-Founder & Scientific Advisor), Shahid M. Nimjee, M.D., Ph.D. (Co-Founder & Chief Scientific Officer)
- **Team size:** ~19 employees
- **Products:** BB-031, BB-025
- **Notable:** Developing the first reversible thrombolytic for acute ischemic stroke, Advanced BB-031 into a Phase 2 RAISE proof-of-concept trial, Dosed first patients in Part B of the Phase 2 stroke trial (October 2025)

## Products & services

- **BB-031** — Lead investigational therapy: a first-in-class RNA aptamer designed to inhibit von Willebrand Factor (vWF) with high specificity, providing rapid-onset, short-acting clot dissolution for acute ischemic stroke. Currently in the Phase 2 RAISE trial.
- **BB-025** — A direct-acting reversal agent designed to specifically bind and neutralize BB-031 within minutes, allowing physicians to switch off thrombolytic activity in the event of bleeding. In Phase 1 testing as of late 2025.

## Achievements

- Developing the first reversible thrombolytic for acute ischemic stroke
- Advanced BB-031 into a Phase 2 RAISE proof-of-concept trial
- Dosed first patients in Part B of the Phase 2 stroke trial (October 2025)
- Began first-in-human Phase 1 testing of reversal agent BB-025 (November 2025)
- Raised $55M financing led by ARCH Venture Partners (January 2024)
- Translated 16 years of academic RNA aptamer research into a clinical pipeline

## Latest updates

- **2025-11** — First participants dosed in Phase 1 study of BB-025, the direct-acting reversal agent.
- **2025-10** — Dosed first patients in Part B of the Phase 2 RAISE stroke trial, unlocked a $27.5M financing tranche, and appointed Julia C. Owens, Ph.D. as CEO.
- **2024-01** — Closed $55M financing led by ARCH Venture Partners to accelerate clinical development.

## Links

- Website: https://baskingbiosciences.com
- LinkedIn: http://www.linkedin.com/company/basking-biosciences-inc

---

Profile page: https://yespress.io/basking-biosciences-inc
Published by YesPress — https://yespress.io
Last updated: 2026-06-16